Business
NeoGenomics To Virtually Participate In The 39th Annual J.P. Morgan Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global
About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, Dr. Lawrence Weiss, Chief Medical Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the virtual 39th Annual J.P. Morgan Healthcare Conference 2021 on Monday, January 11, 2021 at 5:20pm ET.The presentation will be webcast live and accessible online via the investors section of the Company's website, www.neogenomics.com.About NeoGenomics, Inc.NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit http://www.neogenomics.com/.Forward Looking StatementsCertain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company's ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the ...